Ando H, Ishida H, Kiso M, Hasegawa A
Department of Applied Bioorganic Chemistry, Gifu University, Japan.
Carbohydr Res. 1997 May 16;300(3):207-17. doi: 10.1016/s0008-6215(97)00051-7.
Trimeric sialic acid [Neu5Ac alpha(2-->8)Neu5Ac alpha(2-->8)Neu5Ac, 1] residue-containing gangliosides, GT4, alpha(2-->6)GT4 and GT3, have been synthesized for the first time. Methyl [phenyl] 5-acetamido-8-O-[5-acetamido-8-O-(5-acetamido-4, 7, 8, 9-tetra-O-acetyl-3, 5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylono-1", 9'-lactone)-4,7-di-O-acetyl-3,5-dideoxy-D- glycero-alpha-D-galacto-2-nonulopyranosylono-1',9-lactone]-4,7-di- O-acetyl -3,5-dideoxy-2-thio-D- glycero-D-galacto-2-nonulopyranosid]onate (3) was prepared from 1, via lactonization, methyl esterification of the carboxyl group at the reducting end, O-acetylation and conversion of the anomeric acetoxy group into a phenylthio group. Iodonium-promoted glycosylation of 3 with 2-(trimethylsilyl)ethyl 2,6-di-O-benzyl-beta-D-galactopyranoside (5), 2-(trimethylsilyl)ethyl 3-O-benzyl-beta-D-galactopyranoside (6), 2-(trimethylsilyl)ethyl 2-O-benzoyl-3-O-benzyl-beta-D-galactopyranoside (9), and 2-(trimethylsilyl)ethyl 2, 3-di-O-benzyl-beta-D-galactopyranoside (11) gave the corresponding tetrasaccharides (13-15, 17) having the (Neu5Ac)3-Gal structure. The peracylated oligosaccharides 18 and 24 derived from 13 and 17, and the previously reported lactose derivative 29 were converted into the alpha-trichloroacetimidates 20, 26 and 31, and coupled with (2S,3R,4E)-2-azido-3-O-benzoyl-4-octadecene-1,3-diol (21) to afford the corresponding beta-glycosides 22, 27 and 32. These protected azidosphingosine derivatives were each transformed into the target gangliosides GT4, alpha(2-->6)GT4 and GT3 via selective reduction of the azido group, subsequent coupling with octadecanoic acid, O-deacylation and saponification of the methyl ester and lactone groups.
首次合成了含三聚唾液酸[Neu5Acα(2→8)Neu5Acα(2→8)Neu5Ac, 1]残基的神经节苷脂GT4、α(2→6)GT4和GT3。通过内酯化、还原端羧基的甲酯化、O-乙酰化以及异头乙酰氧基转化为苯硫基,从1制备了甲基[苯基]5-乙酰氨基-8-O-[5-乙酰氨基-8-O-(5-乙酰氨基-4,7,8,9-四-O-乙酰基-3,5-二脱氧-D-甘油-α-D-半乳糖-2-壬吡喃糖醛酸-1",9'-内酯)-4,7-二-O-乙酰基-3,5-二脱氧-D-甘油-α-D-半乳糖-2-壬吡喃糖醛酸-1',9-内酯]-4,7-二-O-乙酰基-3,5-二脱氧-2-硫代-D-甘油-D-半乳糖-2-壬吡喃糖苷]酸酯(3)。3与2-(三甲基硅基)乙基2,6-二-O-苄基-β-D-吡喃半乳糖苷(5)、2-(三甲基硅基)乙基3-O-苄基-β-D-吡喃半乳糖苷(6)、2-(三甲基硅基)乙基2-O-苯甲酰基-3-O-苄基-β-D-吡喃半乳糖苷(9)和2-(三甲基硅基)乙基2,3-二-O-苄基-β-D-吡喃半乳糖苷(11)在碘鎓促进下进行糖基化反应,得到具有(Neu5Ac)3-Gal结构的相应四糖(13 - 15, 17)。源自13和17的全酰化寡糖18和24以及先前报道的乳糖衍生物29被转化为α-三氯乙酰亚胺酯20、26和31,并与(2S,3R,4E)-2-叠氮基-3-O-苯甲酰基-4-十八碳烯-1,3-二醇(21)偶联,得到相应的β-糖苷22、27和32。这些受保护的叠氮鞘氨醇衍生物各自通过叠氮基的选择性还原、随后与十八烷酸偶联、甲酯和内酯基团的O-脱酰化和皂化反应转化为目标神经节苷脂GT4、α(2→6)GT4和GT3。